Overview
Essential Thrombocythemia is treated with 3 medications in our database, including Anagrelide, anagrelide, FERRIPROX. 1 of these has manufacturer assistance programs available to help reduce out-of-pocket costs. Medications are manufactured by Takeda, Chiesi reinforcement _Self-correction:_ The user asked for the primary manufacturer/company that owns the rights. Chiesi is the entity. Final string: Chiesi. Patients and caregivers can find copay cards, patient assistance programs, and travel grants for Essential Thrombocythemia treatment below.
Also known as:
Clinical phenotype terms— hover any for plain English:
Sporadic
Usually appears on its own, not inherited from a parent
Adult
Begins in adulthood (age 18 or older)
FDA & Trial Timeline
10 eventsBrigham and Women's Hospital — NA
Novartis Pharmaceuticals — PHASE1
John Mascarenhas — PHASE2
Novartis Pharmaceuticals — PHASE3
Prelude Therapeutics — PHASE1
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Incyte Corporation — PHASE1
Step Pharma, SAS — PHASE1
GlaxoSmithKline — PHASE2
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
2 availableAgrylin
Treatment of patients with essential thrombocythemia to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms.
FERRIPROX
Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program fo
Rare Disease Specialist
Rare Disease Specialist
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Financial Resources
1 resources4 travel grants are also available for Essential thrombocythemia patients — see Travel Grants below ↓
Travel Grants
4 grantsCancerCare Co-pay Assistance for Myeloproliferative Neoplasms
CancerCare
Patients must be diagnosed with Myeloproliferative Neoplasms (ET, PV, or MF) and require financial assistance for treatment, co-pays, or clinical trial-related travel. Specific criteria vary by partner organization, with some requiring household income at or below 500% of the federal poverty level.
Takeda Here2Assist Program
Takeda Oncology
Patients must be US residents at least 18 years old with commercial insurance and a valid prescription for ALUNBRIG. The co-pay assistance program explicitly excludes patients covered by government-sponsored programs like Medicare or Medicaid, although these patients may receive help finding third-party support.
Ferriprox Patient Enrollment (Chiesi USA)
Patients must be U.S. residents with a valid prescription for a Chiesi product and a completed provider start form on file. Financial assistance is restricted to those with commercial insurance, excluding beneficiaries of government-funded programs like Medicare or Medicaid.
Community
No community posts yet. Be the first to share your experience with Essential thrombocythemia.
Start the conversation →Latest news about Essential thrombocythemia
1 articlesCaregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Essential thrombocythemia
What is Essential thrombocythemia?
Essential Thrombocythemia is treated with 3 medications in our database, including Anagrelide, anagrelide, FERRIPROX. 1 of these has manufacturer assistance programs available to help reduce out-of-pocket costs. Medications are manufactured by Takeda, Chiesi reinforcement _Self-correction:_ The user asked for the primary manufacturer/company that owns the rights. Chiesi is the entity. Final string: Chiesi. Patients and caregivers can find copay cards, patient assistance programs, and travel grants for Essential Thrombocythemia treatment below.
How is Essential thrombocythemia inherited?
Essential thrombocythemia follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Essential thrombocythemia typically begin?
Typical onset of Essential thrombocythemia is adult. Age of onset can vary across affected individuals.
Are there clinical trials for Essential thrombocythemia?
Yes — 20 recruiting clinical trials are currently listed for Essential thrombocythemia on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Essential thrombocythemia?
25 specialists and care centers treating Essential thrombocythemia are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.
What treatment and support options exist for Essential thrombocythemia?
2 FDA-approved treatments and 3 patient support programs are currently tracked on UniteRare for Essential thrombocythemia. See the treatments and support programs sections for copay assistance, eligibility, and contact details.